Core Viewpoint - The company, Tasly Pharmaceutical Group Co., Ltd., is set to hold a half-year performance briefing on August 28, 2025, to discuss its operational results and financial status for the first half of 2025, alongside its major shareholders and related parties [2][3]. Group 1: Meeting Details - The meeting will take place on August 28, 2025, from 15:00 to 16:00 [4]. - It will be conducted via an online interactive format on the Panoramic Roadshow platform [4][5]. - Investors can submit questions from August 21 to August 25, 2025, through the investor relations platform or via email [2][5]. Group 2: Participants - Key participants from the company include Mr. Cai Jinyong (Chairman and General Manager), Mr. Yu Jie (Board Secretary), Ms. Wei Jie (Chief Financial Officer), and Ms. Wang Aijian (Independent Director) [4]. Group 3: Post-Meeting Access - After the briefing, investors can access the meeting's details and main content on the Panoramic Roadshow platform [5].

Core Viewpoint - The company, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., announced a half-year performance briefing scheduled for August 28, 2025, to discuss its operational status and future development plans [1][2]. Group 1: Performance Briefing Details - The performance briefing will take place on August 28, 2025, from 15:00 to 16:00 [2]. - Key participants from the company include Chairman Qiu Huawai, President Wu Wendo, and other executives [2]. - Investors can join the briefing via the Panoramic Roadshow platform [3]. Group 2: Investor Interaction - Investors are encouraged to submit questions from August 21 to August 25, 2025, through the Panoramic Investor Relations platform or via email [4]. - The company will address commonly asked questions during the performance briefing [4]. Group 3: Guarantee Matters - The company provided a guarantee of 10 million yuan for its subsidiary, Youyang Pharmaceutical, under the control of Kunming Pharmaceutical Group [8]. - The total guarantee amount for Kunming Pharmaceutical Group's subsidiaries is expected to reach up to 456.15 million yuan for the year 2025 [9]. - As of the announcement date, the total external guarantee balance for Kunming Pharmaceutical Group and its subsidiaries is 118.2 million yuan, which is 2.25% of Kunming's latest audited net assets [16].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600422 证券简称：昆药集团 公告编号：2025-043号 昆药集团股份有限公司 关于召开2025年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 昆药集团股份有限公司（以下简称"公司"）已于2025年8月16日发布公司2025年半年度报告，为便于广 大投资者更全面深入地了解公司2025年半年度经营成果、财务状况，公司计划于2025年8月28日下午 15:00-16:00，联合公司控股股东华润三九医药股份有限公司、公司关联方天士力医药集团股份有限公司 举行2025年半年度网上业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以网络文字互动方式召开，公司将针对2025年半年度的经营成果及财务指标等具体情况 与投资者进行交流和沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、方式 召开时间：2025年8月28日（星期四）下午15:00-16:00 召开地点：全景路演（htt ...

Core Insights - The global malaria cases reached 263 million in 2023, resulting in approximately 600,000 deaths, with 80% of these being children under five years old [1] - China has been recognized as a "malaria-free country" by the World Health Organization since 2021, transitioning from a high-incidence area to a model for malaria elimination [1] Technological Innovations - The Gates Foundation highlights the challenges in global malaria control, including rising malaria cases and stagnation in resource investment, alongside increasing resistance of malaria parasites to artemisinin-based drugs [2] - A new "black box" mosquito monitoring device developed by a research team is designed to address outdoor mosquito transmission challenges, capturing and analyzing mosquito data in real-time [3] - Traditional wisdom is being leveraged to discover new mosquito repellent compounds, with a team identifying six high-activity molecules from over 60,000 compounds, showing promise for environmentally friendly solutions [4] Drug Development Breakthroughs - The ideal malaria drug should be low-dose, low-toxicity, and highly accessible, with a focus on developing single-dose treatments that maintain efficacy for extended periods [5] - Two promising candidate molecules have been identified that can provide 28 days of malaria protection with minimal risk of resistance [5] - The Gates Foundation supports the transition of innovative drugs from research to application, exemplified by a new artemisinin-based drug receiving WHO prequalification [6] Experience Sharing and Global Health Empowerment - China has developed a unique "1-3-7 model" for malaria elimination, which emphasizes rapid case reporting and control measures, and is being adapted for use in other countries [7] - A collaborative project in Tanzania has successfully implemented this model, benefiting approximately 300,000 people and significantly reducing malaria prevalence in intervention areas [8] - The global health landscape faces unprecedented challenges, and China's contributions in malaria control are increasingly significant, transitioning from a participant to a contributor in global health governance [8]

证券日报网讯 8月20日晚间，华润三九发布公告称，公司计划于2025年8月28日（星期四）15：00-16： 00联合公司控股子公司昆药集团股份有限公司、天士力医药集团股份有限公司举办2025年半年度业绩说 明会。 （编辑 任世碧） ...

（文章来源：证券日报） 证券日报网讯 8月20日晚间，昆药集团发布公告称，公司及子/孙公司不存在对控股股东和实际控制人 及其关联人、合并报表外单位提供担保的情形，无逾期担保事项。 ...

证券日报网讯8月20日晚间，昆药集团（600422）发布公告称，公司计划于2025年8月28日15：00-16： 00联合公司控股股东华润三九（000999）医药股份有限公司、公司关联方天士力（600535）医药集团股 份有限公司举行2025年半年度网上业绩说明会。 ...

Group 1 - The company Tianjin Tasly Pharmaceutical Co., Ltd. announced plans to hold a semi-annual performance briefing on August 28, 2025, from 15:00 to 16:00 [2] - The briefing will be conducted in collaboration with its controlling shareholder, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., and its affiliate, Kunming Pharmaceutical Group Co., Ltd. [2]

证券代码：600422 证券简称：昆药集团 公告编号：2025-043 号 昆药集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 8 月 21 日(星期四)至 2025 年 8 月 25 日（星期一）16:00 前访问 全景投资者关系互动平台 （http://ir.p5w.net/zj/），进入问题征集专题页面进行提问，根据活 动时间，选中本次活动或通过公司邮箱(irm.kpc@kpc.com.cn)向公司提问，公司将在说明会上 对投资者普遍关注的问题进行回答。 昆药集团股份有限公司（以下简称"公司"）已于2025年8月16日发布公司2025年半年度报 告，为便于广大投资者更全面深入地了解公司2025年半年度经营成果、财务状况，公司计划 于2025年8月28日下午15:00-16:00，联合公司控股股东华润三九医药股份有限公司、公司关联 方天士力医药集团股份有限公司举行2025年半年度网上业绩说明会，就投资者关心的问题进 行 ...

证券代码：600422 证券简称：昆药集团 公告编号：2025-044 号 昆药集团股份有限公司关于对外担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | 阳制药"） | | | --- | --- | --- | --- | | | | | 华润三九（酉阳）制药有限公司（以下简称"酉 | | | 本次担保金额 | 1,000 万元 | | | 担保对象一 | 实际为其提供的担保余额 | 万元 1,000 | | | | 是否在前期预计额度内 | 是 □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 否 | □不适用：_________ | 注：上述被担保人为昆药集团股份有限公司（以下简称"本公司"、"公司"或"昆 药集团"） 下属全资子公司，不存在关联担保。 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股子 公司对外担保总额（万元） | 45,615 | ...